WO2001034802A3 - Compositions and methods for the therapy and diagnosis of prostate cancer - Google Patents

Compositions and methods for the therapy and diagnosis of prostate cancer Download PDF

Info

Publication number
WO2001034802A3
WO2001034802A3 PCT/US2000/030904 US0030904W WO0134802A3 WO 2001034802 A3 WO2001034802 A3 WO 2001034802A3 US 0030904 W US0030904 W US 0030904W WO 0134802 A3 WO0134802 A3 WO 0134802A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
prostate
prostate cancer
diagnosis
therapy
Prior art date
Application number
PCT/US2000/030904
Other languages
French (fr)
Other versions
WO2001034802A2 (en
WO2001034802A9 (en
Inventor
Jiangchun Xu
Davin C Dillon
Jennifer L Mitcham
Susan L Harlocker
Yuqiu Jiang
Steven G Reed
Michael D Kalos
Marc W Retter
John A Stolk
Craig H Day
Yasir A W Skeiky
Aijun Wang
Original Assignee
Corixa Corp
Jiangchun Xu
Davin C Dillon
Jennifer L Mitcham
Susan L Harlocker
Yuqiu Jiang
Steven G Reed
Michael D Kalos
Marc W Retter
John A Stolk
Craig H Day
Yasir A W Skeiky
Aijun Wang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/439,313 external-priority patent/US6329505B1/en
Application filed by Corixa Corp, Jiangchun Xu, Davin C Dillon, Jennifer L Mitcham, Susan L Harlocker, Yuqiu Jiang, Steven G Reed, Michael D Kalos, Marc W Retter, John A Stolk, Craig H Day, Yasir A W Skeiky, Aijun Wang filed Critical Corixa Corp
Priority to JP2001537498A priority Critical patent/JP2004537252A/en
Priority to US10/129,909 priority patent/US7048931B1/en
Priority to AU16565/01A priority patent/AU1656501A/en
Priority to CA002391369A priority patent/CA2391369A1/en
Priority to EP00979155A priority patent/EP1230364A2/en
Publication of WO2001034802A2 publication Critical patent/WO2001034802A2/en
Publication of WO2001034802A3 publication Critical patent/WO2001034802A3/en
Publication of WO2001034802A9 publication Critical patent/WO2001034802A9/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464493—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; Prostatic acid phosphatase [PAP]; Prostate-specific G-protein-coupled receptor [PSGR]
    • A61K39/464494—Prostate specific antigen [PSA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Compositions and methods for the therapy and diagnosis of cancer, such as prostate cancer, are disclosed. Compositions may comprise one or more prostate-specific proteins, immunogenic portions thereof, or polynucleotides that encode such portions. Alternatively, a therapeutic composition may comprise an antigen presenting cell that expresses a prostate-specific protein, or a T cell that is specific for cells expressing such a protein. Such compositions may be used, for example, for the prevention and treatment of diseases such as prostate cancer. Diagnostic methods based on detecting a prostate-specific protein, or mRNA encoding such a protein, in a sample are also provided.
PCT/US2000/030904 1999-11-12 2000-11-09 Compositions and methods for the therapy and diagnosis of prostate cancer WO2001034802A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP2001537498A JP2004537252A (en) 1999-11-12 2000-11-09 Compositions and methods for treatment and diagnosis of prostate cancer
US10/129,909 US7048931B1 (en) 2000-11-09 2000-11-09 Compositions and methods for the therapy and diagnosis of prostate cancer
AU16565/01A AU1656501A (en) 1999-11-12 2000-11-09 Compositions and methods for the therapy and diagnosis of prostate cancer
CA002391369A CA2391369A1 (en) 1999-11-12 2000-11-09 Compositions and methods for the therapy and diagnosis of prostate cancer
EP00979155A EP1230364A2 (en) 1999-11-12 2000-11-09 Compositions and methods for the therapy and diagnosis of prostate cancer

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US09/439,313 US6329505B1 (en) 1997-02-25 1999-11-12 Compositions and methods for therapy and diagnosis of prostate cancer
US09/439,313 1999-11-12
US44368699A 1999-11-18 1999-11-18
US09/443,686 1999-11-18

Publications (3)

Publication Number Publication Date
WO2001034802A2 WO2001034802A2 (en) 2001-05-17
WO2001034802A3 true WO2001034802A3 (en) 2002-04-04
WO2001034802A9 WO2001034802A9 (en) 2002-08-08

Family

ID=27032000

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/030904 WO2001034802A2 (en) 1999-11-12 2000-11-09 Compositions and methods for the therapy and diagnosis of prostate cancer

Country Status (5)

Country Link
EP (1) EP1230364A2 (en)
JP (1) JP2004537252A (en)
AU (1) AU1656501A (en)
CA (1) CA2391369A1 (en)
WO (1) WO2001034802A2 (en)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030125536A1 (en) * 1996-01-11 2003-07-03 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US7241876B2 (en) 1996-01-11 2007-07-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US6828431B1 (en) 1999-04-09 2004-12-07 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US7033827B2 (en) 1997-02-25 2006-04-25 Corixa Corporation Prostate-specific polynucleotide compositions
US6894146B1 (en) 1997-02-25 2005-05-17 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6759515B1 (en) 1997-02-25 2004-07-06 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6630305B1 (en) 1999-11-12 2003-10-07 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6620922B1 (en) 1997-02-25 2003-09-16 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6657056B2 (en) 1997-02-25 2003-12-02 Corixa Corporation Compounds for immunotherapy of prostate cancer and methods for their use
US6800746B2 (en) 1997-02-25 2004-10-05 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6818751B1 (en) 1997-08-01 2004-11-16 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US20030185830A1 (en) 1997-02-25 2003-10-02 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US7202342B1 (en) 1999-11-12 2007-04-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6329505B1 (en) 1997-02-25 2001-12-11 Corixa Corporation Compositions and methods for therapy and diagnosis of prostate cancer
US6465611B1 (en) 1997-02-25 2002-10-15 Corixa Corporation Compounds for immunotherapy of prostate cancer and methods for their use
US7517952B1 (en) 1997-02-25 2009-04-14 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6943236B2 (en) 1997-02-25 2005-09-13 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
CA2286304C (en) 1997-04-10 2007-08-07 Diagnocure Inc. Pca3, pca3 genes, and methods of use
US7037667B1 (en) 1998-06-01 2006-05-02 Agensys, Inc. Tumor antigen useful in diagnosis and therapy of prostate and colon cancer
US20030149531A1 (en) 2000-12-06 2003-08-07 Hubert Rene S. Serpentine transmembrane antigens expressed in human cancers and uses thereof
ATE437947T1 (en) 1998-06-01 2009-08-15 Agensys Inc SERPENT TRANS MEMBRANE ANTIGENS EXPRESSED IN HUMAN CANCER AND THEIR USES
US6833438B1 (en) 1999-06-01 2004-12-21 Agensys, Inc. Serpentine transmembrane antigens expressed in human cancers and uses thereof
US6902892B1 (en) 1998-10-19 2005-06-07 Diadexus, Inc. Method of diagnosing, monitoring, staging, imaging and treating prostate cancer
US6943235B1 (en) 1999-04-12 2005-09-13 Agensys, Inc. Transmembrane protein expressed in prostate cancer
EP1222266B1 (en) 1999-09-29 2006-03-29 Diagnocure Inc. Pca3 messenger rna in benign and malignant prostate tissues
US7361338B2 (en) 1999-10-05 2008-04-22 Agensys, Inc. Methods to inhibit growth of prostate cancer cells
US6790631B1 (en) 1999-10-05 2004-09-14 Agensys, Inc. G protein-coupled receptor up-regulated in prostate cancer and uses thereof
ATE354663T1 (en) * 1999-10-07 2007-03-15 Corixa Corp A MYCOBACTERIUM TUBERCULOSIS CODING SEQUENCE FOR EXPRESSING HETEROLOGUE PROTEINS
US20020048777A1 (en) 1999-12-06 2002-04-25 Shujath Ali Method of diagnosing monitoring, staging, imaging and treating prostate cancer
HUP0203968A3 (en) * 2000-01-14 2004-09-28 Corixa Corp Seattle Compositions and methods for the therapy and diagnosis of prostate cancer
AU2001249549A1 (en) * 2000-03-27 2001-10-08 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US20020009455A1 (en) * 2000-04-27 2002-01-24 Ted Lau DNA encoding a novel PROST 03 polypeptide
SI1542732T1 (en) 2000-06-20 2010-01-29 Corixa Corp Csc The United Sta Fusion proteins of mycobacterium tuberculosis
EP1328549A4 (en) * 2000-10-03 2004-10-06 Human Genome Sciences Inc Human prostate specific g-protein receptor hpraj70
US7048931B1 (en) 2000-11-09 2006-05-23 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
CA2443123A1 (en) 2001-04-10 2002-10-24 Agensys, Inc. Nuleic acids and corresponding proteins useful in the detection and treatment of various cancers
US6897024B2 (en) 2001-05-31 2005-05-24 Stichting Katholieke Universiteit More Particularly The University Medical Centre Nijmegen Nucleic acid molecules comprising the promoter for PCA3, and uses thereof
WO2003022995A2 (en) 2001-09-06 2003-03-20 Agensys, Inc. Nucleic acid and corresponding protein entitled steap-1 useful in treatment and detection of cancer
US7494646B2 (en) 2001-09-06 2009-02-24 Agensys, Inc. Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
EP1511768B1 (en) * 2002-06-11 2007-04-11 GlaxoSmithKline Biologicals S.A. Immunogenic compositions
US20040081653A1 (en) 2002-08-16 2004-04-29 Raitano Arthur B. Nucleic acids and corresponding proteins entitled 251P5G2 useful in treatment and detection of cancer
CA2513780C (en) 2003-02-07 2014-12-30 Diagnocure Inc. Method to detect prostate cancer from a urine sample
US7834163B2 (en) 2003-06-26 2010-11-16 Exonhit Therapeutics S.A. Prostate specific genes and the use thereof as targets for prostate cancer therapy
NZ550816A (en) 2004-04-22 2009-12-24 Agensys Inc Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
CA2491067A1 (en) 2004-12-24 2006-06-24 Stichting Katholieke Universiteit Mrna rations in urinary sediments and/or urine as a prognostic marker for prostate cancer
RU2639543C9 (en) 2006-10-27 2018-06-14 Дженентек, Инк. Antibodies and immunoconjugates and their applications
GB201513921D0 (en) 2015-08-05 2015-09-23 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
JP7247101B2 (en) 2017-04-03 2023-03-28 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Antibody that binds to STEAP-1

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0317141A2 (en) * 1987-11-13 1989-05-24 Becton, Dickinson and Company Method of purging residual tumor cells in vitro with lymphokine activated cytotoxic cells
WO1997033909A2 (en) * 1996-03-15 1997-09-18 Corixa Corporation Compounds and methods for immunotherapy and immunodiagnosis of prostate cancer
WO1998037093A2 (en) * 1997-02-25 1998-08-27 Corixa Corporation Compounds for immunotherapy of prostate cancer and methods for their use
WO1998037418A2 (en) * 1997-02-25 1998-08-27 Corixa Corporation Compounds for immunodiagnosis of prostate cancer and methods for their use
WO2000004149A2 (en) * 1998-07-14 2000-01-27 Corixa Corporation Compositions and methods for therapy and diagnosis of prostate cancer
WO2001025272A2 (en) * 1999-10-04 2001-04-12 Corixa Corporation Compositions and methods for therapy and diagnosis of prostate cancer

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998050567A1 (en) * 1997-05-02 1998-11-12 Abbott Laboratories Reagents and methods useful for detecting diseases of the prostate
AU4823599A (en) * 1998-06-22 2000-01-10 Incyte Pharmaceuticals, Inc. Prostate cancer-associated genes

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0317141A2 (en) * 1987-11-13 1989-05-24 Becton, Dickinson and Company Method of purging residual tumor cells in vitro with lymphokine activated cytotoxic cells
WO1997033909A2 (en) * 1996-03-15 1997-09-18 Corixa Corporation Compounds and methods for immunotherapy and immunodiagnosis of prostate cancer
WO1998037093A2 (en) * 1997-02-25 1998-08-27 Corixa Corporation Compounds for immunotherapy of prostate cancer and methods for their use
WO1998037418A2 (en) * 1997-02-25 1998-08-27 Corixa Corporation Compounds for immunodiagnosis of prostate cancer and methods for their use
WO2000004149A2 (en) * 1998-07-14 2000-01-27 Corixa Corporation Compositions and methods for therapy and diagnosis of prostate cancer
WO2001025272A2 (en) * 1999-10-04 2001-04-12 Corixa Corporation Compositions and methods for therapy and diagnosis of prostate cancer

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBL 20 February 1998 (1998-02-20), ALBERS C ET AL: "Human alpha-methylacyl-CoA racemase cDNA sequence", XP002176408 *
SCHMIDT-WOLF G D ET AL: "Activated T cells and cytokine-induced CD3+CD56+ killer cells.", ANNALS OF HEMATOLOGY, vol. 74, no. 2, 1997, pages 51 - 56, XP002176407, ISSN: 0939-5555 *
SJOGREN H O: "Therapeutic immunization against cancer antigens using genetically engineered cells", IMMUNOTECHNOLOGY, ELSEVIER SCIENCE PUBLISHERS BV, NL, vol. 3, no. 3, 1 October 1997 (1997-10-01), pages 161 - 172, XP004097000, ISSN: 1380-2933 *

Also Published As

Publication number Publication date
WO2001034802A2 (en) 2001-05-17
EP1230364A2 (en) 2002-08-14
WO2001034802A9 (en) 2002-08-08
JP2004537252A (en) 2004-12-16
CA2391369A1 (en) 2001-05-17
AU1656501A (en) 2001-06-06

Similar Documents

Publication Publication Date Title
WO2001034802A3 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
WO2001025272A3 (en) Compositions and methods for therapy and diagnosis of prostate cancer
WO2000004149A3 (en) Compositions and methods for therapy and diagnosis of prostate cancer
WO2001040269A3 (en) Compositions and methods for therapy and diagnosis of breast cancer
WO2001096388A8 (en) Compositions and methods for the therapy and diagnosis of colon cancer
WO2001000828A3 (en) Compositions and methods for the therapy and diagnosis of lung cancer
WO2001096390A3 (en) Compositions and methods for the therapy and diagnosis of colon cancer
WO2000060076A3 (en) Compositions for the treatment and diagnosis of breast cancer and methods for their use
WO2001075171A3 (en) Methods, compositions and kits for the detection and monitoring of breast cancer
WO2001079286A3 (en) Compositions and methods for the therapy and diagnosis of breast cancer
WO2000060077A3 (en) Compounds for therapy and diagnosis of lung cancer and methods for their use
WO2002083070A3 (en) Compounds for immunotherapy and diagnosis of colon cancer and methods for their use
WO2000037643A3 (en) Compounds for immunotherapy and diagnosis of colon cancer and methods for their use
WO2001051633A3 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
WO2001073032A3 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
WO2001072295A3 (en) Compositions and methods for the therapy and diagnosis of lung cancer
WO2001073027A3 (en) Compositions and methods for therapy and diagnosis of colon cancer
WO2002004514A8 (en) Compositions and methods for the therapy and diagnosis of lung cancer
WO2000052165A3 (en) Compositions and methods for breast cancer therapy and diagnosis
WO2001049716A3 (en) Compounds for immunotherapy and diagnosis of colon cancer and methods for their use
WO2000078960A3 (en) Compositions and methods for the therapy and diagnosis of breast cancer
WO2001057207A3 (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
WO2001077168A3 (en) Compositions and methods for the therapy and diagnosis of lung cancer
WO2001051513A3 (en) Ovarian tumor-associated sequences
WO2001070976A3 (en) Compositions and methods for the therapy and diagnosis of ovarian and endometrial cancer

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2391369

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2001 537498

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2000979155

Country of ref document: EP

AK Designated states

Kind code of ref document: C2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGES 1/10-10/10, DRAWINGS, REPLACED BY NEW PAGES 1/10-10/10; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

WWP Wipo information: published in national office

Ref document number: 2000979155

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10129909

Country of ref document: US

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642